Sotan is a targeted antitumor drug, with the trade name Sunitinib, which is mainly used for targeted therapy of advanced kidney cancer. Some studies have shown that the application of sotan treatment can effectively extend the survival cycle of some patients with advanced kidney cancer, even to more than two years. Targeted anti-tumor drugs should be used with clear indications. Patients need to undergo relevant genetic tests, and if they are suggested to have genetic mutations, they can apply Sotan treatment with relatively better therapeutic effectiveness. However, it should be noted that there are adverse reactions or contraindications to the drug. While taking targeted drug therapy, patients should also go to the hospital for regular follow-up to monitor the effectiveness and safety of the drug. It is also necessary to clarify the patient’s tolerance of the drug, and to follow up for a long time whether the dose of the drug needs to be adjusted or combined with other drugs.